Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pathol.2023.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent pseudolymphomatous reaction to ear piercing: 20-year history.
Pathology
October 2023
Clementine Churchill Hospital, Sudbury Hill, Marlow, UK.
Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID-19 vaccination: A reactive lymphomatoid papulosis-like eruption and a bona fide lymphoma.
J Cutan Pathol
March 2023
Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Article Synopsis
- - COVID-19 infection and vaccination can lead to various skin and immune reactions, with some cases resembling lymphoma.
- - Two patients with skin issues post-vaccination exhibited abnormal T-cell infiltration, with one improving and the other worsening after a subsequent COVID-19 infection.
- - The findings suggest that the immune response from the vaccine or infection might trigger lymphoma in individuals predisposed to such disorders, highlighting the difficulty in distinguishing these cases from non-cancerous reactions.
MYC-Nonamplified Secondary Lymphatic-Type Angiosarcoma With Prominent Lymphocytic Infiltrate Following Radiation Therapy for Myxoid Liposarcoma.
Am J Dermatopathol
December 2022
Department of Pathology and Laboratory Medicine, and.
Cutaneous angiosarcomas (AS) are uncommon and morphologically heterogeneous. Recently, a distinctive lymphatic-type AS with prominent lymphocytic infiltrate has been observed. Although conventional AS typically bear poor prognosis, lymphatic-type AS with prominent lymphocytic infiltrate and pseudolymphomatous AS show prolonged survival with rare extracutaneous spread.
View Article and Find Full Text PDFTalimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
J Cutan Pathol
November 2021
Department of Medicine, Division of Dermatology, The Ohio State University, Columbus, Ohio, USA.
Talimogene laherparepvec (TVEC) is a genetically modified herpes simplex virus-1 approved as an intralesional oncolytic immunotherapy for the treatment of advanced melanoma. Cutaneous reactions at the site of injection may mimic recurrent or progressive melanoma; histopathological findings have included chronic granulomatous dermatitis, neutrophilic dermatitis, lymphocytic dermatitis, and pigment incontinence. We report a 39-year-old male with metastatic stage IIIc melanoma treated with TVEC with clinical regression of melanoma lesions that later developed pink nodules at sites of prior injection.
View Article and Find Full Text PDFPseudolymphomatous cutaneous angiosarcoma: a report of 2 new cases arising in an unusual setting.
J Cutan Pathol
September 2013
Section of Dermatology, University of Genova, Genova, Italy; Department of Pathology, University of Genova, Genova, Italy.
Pseudolymphomatous cutaneous angiosarcoma represents a rare, relatively new variant of cutaneous angiosarcoma exhibiting a prominent inflammatory lymphoid infiltrate that can mask the underlying vascular malignant proliferation and mimic a lymphomatous or pseudolymphomatous process. We describe the clinicopathologic characteristics of two new cases of pseudolymphomatous cutaneous angiosarcoma whose originality lies in the unusual setting from which they have arisen. In fact, the first case was an exceedingly lymphocyte-rich recurrence of a typical epithelioid cutaneous angiosarcoma whose primary lesion that was almost devoid of inflammatory infiltrate underwent surgical excision and radiotherapy while the second one was an unexpected histopathological finding associated with a basal cell carcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!